BREAKING🔔 The 9th preprint from G2P-Japan🇯🇵 is out at @biorxivpreprint. We evaluated the effects of 8 therapeutic monoclonal antibodies against new #Omicron subvariants such as BA.2.11, BA.2.12.1, BA.4 and BA.5. Please RT. 1/5
Recently, the Omicron subvariants bearing additional mutations in the BA.2 spike emerged in multiple countries - e.g., BA.2.11 (+L452R) in France🇫🇷, BA.2.12.1 (+L452Q/S704L) in US🇺🇸, and BA.4 and BA.5 (+L452R/HV69-70del/F486V/R493Q) in South Africa🇿🇦. 2/5
In this study, we evaluated the sensitivity of these Omicron subvariants to 8 therapeutic monoclonal antibodies, bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab, imdevimab, tixagevimab and sotrovimab. 3/5
BREAKING🔔 The 8th paper from G2P-Japan🇯🇵 is out at Cell @CellCellPress. We elucidated the virological characteristics (transmissibility, pathogenicity and immune resistance etc.) of SARS-CoV-2 #Omicron BA.2 variant. Please RT. 1/5
1⃣ Statistical analysis shows that the effective reproduction number of BA.2 is ~1.4-fold higher than that of BA.1. 2/5
2⃣ The humoral immunity induced by 2-dose vaccine and BA.1 infection is less functional against BA.2. However, the humoral immunity induced by 3-dose vaccine and '2-dose vaccine + BA.1 infection' efficiently blocks BA.2. 3/5
1⃣ Statistical analysis shows that the effective reproduction number of BA.2 is 1.4-fold higher than that of BA.1. 2/5
2⃣ Neutralization experiments show that the vaccine-induced humoral immunity fails to function against BA.2 like BA.1, and notably, the antigenicity of BA.2 is different from BA.1. 3/5